Fast track to MS drug.
Sheridan
Cormac
C
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002986:Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000191:economics*; D000069442:Natalizumab; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab